AMERICAN CRYOSTEM Corp

CIK:0001468679|SEC Filings

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenues
Total Revenues	$ 42,599	$ 129,800	$ 135,719	$ 383,335
Less Cost of Revenues	(4,781)	(582)	(26,658)	(8,672)
Gross Margin	37,818	129,218	109,061	374,663
Operating Expenses
Research & Development	15,563	119,570	210,769	298,889
Laboratory Expense	20,213	17,712	56,835	50,056
Sales & Marketing	16,820	1,186	17,477	5,196
Professional Fees	35,453	39,836	156,501	142,026
Consulting Expense	160,642	296,109	929,208	296,109
Bad Debt Expense	65,680	990	65,320	990
General & Administrative	100,272	95,589	342,672	346,798
Total Operating Expenses	414,643	570,992	1,778,782	1,140,064
Net Loss from Operations	(376,825)	(441,774)	(1,669,721)	(765,401)
Other Income (Expenses):
Interest Income	2		2	3
Laboratory Rent				3,000
Gain on write off of Liability				24,000
Exchange Rate				86
Interest Expense	(21,453)	(21,283)	(66,253)	(59,422)
Interest Expense (beneficial conversion feature-debenture)	(3,413)	(3,413)	(10,239)	(19,499)
Net Loss	$ (401,689)	$ (466,470)	$ (1,746,211)	$ (817,233)
Basic & Fully Diluted Net Income (Loss) per Common Share:	$ (0.009)	$ (0.008)	$ (0.037)	$ (0.014)
Weighted Average of Common Shares Outstanding - Basic & fully diluted	43,995,180	60,496,428	47,063,587	60,141,838
Health Care, Other [Member]
Revenues
Total Revenues	$ 39,599	$ 4,800	$ 132,119	$ 7,575
Product [Member]
Revenues
Total Revenues	3,000		3,600	760
Royalty [Member]
Revenues
Total Revenues		$ 125,000		$ 375,000

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating Activities:
Net loss	$ (1,746,211)	$ (817,233)
Adjustments to reconcile net loss items not requiring the use of cash:
Gain on Write Off of Liability		(24,000)
Common Stock for Services		41,000
Prepaid Expenses paid in Common Stock	50,000
Depreciation & Amortization Expense	63,349	56,640
Interest paid in Common Stock	59,310	44,346
Bad Debt Expense	65,320	990
Stock Compensation Expense	794,558	296,109
Interest Expense - Beneficial Conversion Feature	10,239	19,499
Changes in operating assets and liabilities
Accounts Receivable	63,923	(375,550)
Inventory	(3,782)	(5,381)
Prepaid expense	16,248	80,000
Operating Lease Asset	(73,995)
Accounts Payable and Accrued Expenses	(151,673)	188,819
Operating Lease	54,059
Accrued Executive Salaries	259,250	180,000
Deferred Revenue	(94,355)
Net cash used by operations	(699,080)	(314,761)
Investing activities:
Patents development	(73,202)	(35,187)
Net cash used by investing activities	(73,202)	(35,187)
Financing activities:
Issuance of Common Shares	813,500	143,000
Issuance of Convertible Notes		150,000
Paid down Finance Lease	(23,362)	(26,722)
Payable to related party	(23,343)	49,279
Net cash provided by financing activities	766,795	315,557
Net change in cash	(5,487)	(34,391)
Cash balance at beginning of the period	8,244	41,760
Cash balance at end of the period	2,757	7,369
Supplemental disclosures of cash flow information:
Interest paid during the period	3,582	1,435
Income taxes paid during the period

Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2022	Sep. 30, 2021
Current Assets:
Cash	$ 2,757	$ 8,244
Accounts Receivable - net of allowance for bad debt	14,859	78,782
Inventory	21,716	17,934
Deferred Contract Expense	39,370	39,370
Prepaid Expenses	36,371	52,619
Total Current Assets	115,073	196,949
Other Assets:
Investment in Baoxin - at cost	244,919	244,919
Security Deposit	13,540	13,540
Patents, Patents Development and Trademarks - net of accumulated amortization	434,572	371,849
Fixed Assets - net of accumulated depreciation	103,652	113,483
Finance Lease - Right-of-Use-Asset	92,413	115,516
Right of Use Asset	54,059
Total Assets	1,058,228	1,056,256
Current Liabilities:
Accounts Payable & Accrued Expenses	375,371	553,120
Legal & Accounting Payable	123,900	97,824
Bridge Notes Payable	226,500	226,500
Convertible Notes Payable	716,370	573,500
PPP Loan - Current Portion	23,407	23,407
Finance Lease Liability	22,801	34,512
Operating Lease Liability	28,505
Deferred Revenue	27,690	122,045
Total Current Liabilities	1,544,544	1,630,908
Long Term Liabilities:
Accrued Executive Salaries	1,239,436	980,186
Convertible Notes Payable		132,631
Finance Lease Liability		11,651
Operating Lease Liability	25,554
Note Payable to Related Party	125,090	147,775
Payable to Related Party		658
Total Liabilities	2,934,624	2,903,809
Commitments and Contingencies	0	0
Preferred Stock - $.0001 par value, 50,000,000 shares authorized, 1,000,000 shares issued and outstanding at June 30, 2022 and 0 shares issued and outstanding at September 30, 2021	100	0
Common Stock - $.001 par value, 300,000,000 shares authorized, 44,181,896 shares issued and outstanding at June 30, 2022 and 61,374,524 issued and outstanding at September 30, 2021	44,183	61,376
Additional Paid in Capital	19,103,297	17,368,836
Accumulated Deficit	(21,023,976)	(19,277,765)
Total Shareholders’ Deficit	(1,876,396)	(1,847,553)
Total Liabilities & Shareholders’ Deficit	$ 1,058,228	$ 1,056,256